ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/VEGFR3
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/VEGFR3
2
trial(s) found.
NCT07235293
Advanced
Phase 2
Recruiting
A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer (
DSP107-003
)
VEGFR1/2/3 inhibitor
anti-PD-L1 monoclonal antibody
bifunctional CD47/4-1BB fusion protein
+ VEGFR3 inhibitor
Colorectal adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12607000589482
Advanced
Phase 3
Recruiting
Phase III randomised study of Brivanib Alaninate (BMS-582664) in combination with Cetuximab (Erbitux 'Registered trade mark') versus placebo in combination with Cetuximab (Erbitux 'Registered trade mark') in patients with K-Ras wild type tumours previously treated with combination chemotherapy for metastatic colorectal carcinoma to compare overall survival. (
CO.20
)
FGFR1 inhibitor
VEGFR1/2/3 inhibitor
anti-EGFR monoclonal antibody
placebo
+ VEGFR3 inhibitor
Colorectal adenocarcinoma
NSW
2999 - Unspecified - Clinical Trial Site NSW - GenesisCare
QLD
4999 - Unspecified - Clinical Trial Site QLD
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Recruitment Country and State
NSW (2)
QLD (2)
SA (2)
WA (2)
VIC (1)
Phase
Phase 2 (1)
Phase 3 (1)
Trial Type
Advanced (2)
Cancer Therapy Class
VEGFR1
100%
VEGFR2
100%
VEGFR3
100%
PD-1/PD-L1
50%
PD-L1
50%
EGFR
50%
FGFR
50%
FGFR1
50%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3011 - Footscray - Footscray Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
3168 - Clayton - Monash Medical Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2999 - Unspecified - Clinical Trial Site NSW - GenesisCare (1)
4999 - Unspecified - Clinical Trial Site QLD (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6000 - Perth - Royal Perth Hospital (1)
NA
Cancer Type
Cancer
Colorectal adenocarcinoma
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Solid tumour
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy